Cardiovascular · AntihypertensiveRegulatory Approvalregulatorymid-term

FDA Grants AP Status for Losartan Potassium ANDA090382 by Strides Pharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Strides Pharma12 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 6:32:00 AM

Assessment confidence: 71% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The FDA's approval of Strides Pharma's ANDA for Losartan Potassium represents a significant regulatory milestone that could shift competitive dynamics in the antihypertensive market. Portfolio teams must evaluate the implications for market share and pricing strategies as new entrants challenge established players. Regulatory context from FDA (FDA AP — LOSARTAN POTASSIUM (SUPPL)) supports the near-term read. Assessment grounded in 21 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for Losartan and similar products. The strongest clinical anchor is Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in Children (ClinicalTrials.gov), mechanism alignment (io ). In Cardiovascular · Antihypertensive, 8 regulatory and 1 competitive items passed relevance filtering for Strides Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Pfizer's Marstacimab (HYMPAVZI) Supplement (Humanexa Signals) — sponsor/company relevance (pfizer). This approval may enhance Strides Pharma's position in the antihypertensive market, increasing competition against established players.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LOSARTAN POTASSIUM (SUPPL) (FDA). Entity match (strides pharma); Regulatory pathway relevance (nda).

Key Risks

Elevated medium regulatory exposure for Strides Pharma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population) could weigh on Strides Pharma through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (Status Epilepticus Population Study (STEPS)) could weigh on Strides Pharma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Strides Pharma's entry into the market with an approved generic could pressure pricing and market share for existing brands, impacting overall revenue in the antihypertensive segment.
Upside for Strides Pharma may improve if A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for Losartan and similar products.

What Would Change This Assessment

This becomes more urgent if Monitor the launch timeline and market entry strategies of Strides Pharma for Losartan Potassium.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LOSARTAN POTASSIUM (SUPPL)
FDAhigh relevance
Entity match (strides pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LOSARTAN POTASSIUM (SUPPL)
FDAhigh relevance
Entity match (losartan potassium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LOSARTAN POTASSIUM (SUPPL)
FDAhigh relevance
Entity match (losartan potassium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (ORIG)
FDAhigh relevance
Entity match (losartan potassium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LOSARTAN POTASSIUM (SUPPL)
FDAhigh relevance
Entity match (losartan potassium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LOSARTAN POTASSIUM (SUPPL)
FDAhigh relevance
Entity match (losartan potassium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (ORIG)
FDAhigh relevance
Entity match (losartan potassium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in Children
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Status Epilepticus Population Study (STEPS)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for Pfizer's Marstacimab (HYMPAVZI) Supplement
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)

Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Reduced antihypertensive treatment with maintained ambulatory blood pressure control following weight loss in type 2 diabetes.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of different caffeine doses on fat oxidation and cardiovascular response during exercise at FATmax in overweight/obese female college students.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Strides Pharma
Losartan Potassium

Commercial impact

medium

Strides Pharma's entry into the market with an approved generic could pressure pricing and market share for existing brands, impacting overall revenue in the antihypertensive segment.

Regulatory impact

medium

The approval indicates a successful regulatory pathway for Strides Pharma, which may encourage similar applications from competitors, affecting the overall regulatory landscape for antihypertensive drugs.

What to watch

Monitor the launch timeline and market entry strategies of Strides Pharma for Losartan Potassium.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.